Streetbeat News

Revenues

HLT

Hilton Worldwide's CFO reported a significant 73% YoY increase in Revenue Per Available Room (RevPAR) in China for the quarter. Additionally, Group RevPAR rose by 6% YoY, attributed to an uptick in small company meetings and convention demand.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:26 pm

DAY

Dayforce projects Q1 2024 revenue between $424M-$427M, slightly below the $427.81M estimate, and FY24 revenue between $1.72B-$1.73B, under the $1.74B estimate. The company anticipates a 14%-15% revenue increase in Q1 and a 14% increase for FY24 on a GAAP and constant currency basis. Dayforce expects a decline in other recurring revenue due to sunsetting legacy solutions but predicts an increase in PowerPay recurring revenue. Adjusted EBITDA is forecasted at $123M-$126M for Q1 and $480M-$495M for FY24, reflecting investments in global expansion and the Dayforce rebrand and eloomi acquisition.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 3:19 pm

HLNE

Hamilton Lane (NASDAQ:HLNE) has been the subject of 4 analyst reviews over the last three months, all indicating an 'Indifferent' stance. Despite this, price targets have been raised, with the current average target at $111.25, reflecting a 10.7% increase from the previous $100.50. The company faces challenges with a -17.28% revenue decline as of September 30, 2023, but shows financial strength with a high net margin of 33.1%, ROE of 9.36%, and ROA of 3.28%. Its debt-to-equity ratio is well-managed at 0.6.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 3:00 pm

CRLBF

TCNNF

Pennsylvania Governor Josh Shapiro has proposed the legalization of adult-use cannabis to generate over $250 million in annual revenue and combat the black market. The proposal includes a July 1, 2024, effective date for legalization, with sales starting January 1, 2025, and allocates $5 million towards restorative justice initiatives. Representatives from Cresco Labs and Trulieve participated in a House Health Subcommittee hearing discussing marijuana policy reform.

Portfolio Pulse from Nina Zdinjak

February 07, 2024 | 2:47 pm

IMMX

Immix Biopharma, Inc. (NASDAQ:IMMX) has been granted the European Union Orphan Drug Designation (ODD) for NXC-201, a treatment for AL Amyloidosis. This designation offers 10 years of market exclusivity in the EU, access to centralized authorization, reduced fees, and other benefits. The U.S. prevalence of relapsed/refractory AL Amyloidosis is increasing by 12% annually, with an estimated 29,712 patients in 2023. The company believes NXC-201 could be a one-time treatment option for this condition, with a favorable tolerability profile and potential for expansion into other autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 2:41 pm

EH

EHang Holdings Limited (NASDAQ:EH) announced a suggested retail price of $410,000 for its EH216-S pilotless eVTOL aircraft for global markets outside China, effective from April 1, 2024. The EH216-S features autonomous flight, electric propulsion, safety features, and intelligent systems for cluster management, aiming at various urban air mobility applications. It also secured the world's first Type Certificate and Standard Airworthiness Certificate for pilotless passenger-carrying eVTOL aircraft from the CAAC in 2023, highlighting EHang's commitment to safety and quality. This pricing strategy is intended to meet international demand and promote the adoption of innovative urban air mobility solutions.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 2:14 pm

LRN

Stride, Inc. (LRN) has been named a qualified vendor for Michigan's $150M Tutoring Initiative, expanding its tutoring services to students across Arkansas. This designation allows Stride Tutoring to be a part of a significant educational effort aimed at enhancing student learning and achievement.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 2:08 pm

DT

Dynatrace (NYSE:DT) received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for DT has been raised to $67.1, indicating a 16.94% increase from the previous target. Analysts from firms like Rosenblatt, Scotiabank, and JMP Securities have adjusted their ratings and price targets, reflecting optimism about Dynatrace's market position and financial performance, including a notable revenue growth rate of 25.91% as of September 30, 2023.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 2:00 pm

TW

Tradeweb Markets (NASDAQ:TW) has seen a positive shift in analyst ratings, with an average 12-month price target of $109.0, up 8.46% from the previous target. Four analysts have updated their ratings, all raising their price targets, indicating a bullish outlook on the company. Tradeweb Markets, a leading fixed-income trading platform, has shown solid revenue growth and exceptional financial performance, despite a market capitalization below industry averages and an ROE below industry benchmarks.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 2:00 pm

GEHC

GE HealthCare Techs (NASDAQ:GEHC) has received mixed analyst ratings over the last three months, with a recent shift towards a more bullish outlook. The average 12-month price target has been adjusted to $79.00, down from $86.00, reflecting a decrease of 8.14%. Analysts from Mizuho, Morgan Stanley, Jefferies, and UBS have updated their ratings and price targets, indicating varied expectations for the company's performance. GE HealthCare Techs, a leader in medical technology and diagnostics, has shown solid revenue growth but faces challenges in net margin, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 2:00 pm